Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed malignancy not amenable to curative surgery, radiotherapy, or chemotherapy~* Tumor types may include any of the following:~  * Any solid tumor including, but not limited to, head and neck, breast, lung, gastrointestinal, genitourinary, melanoma, and sarcoma~ * Primary CNS neoplasms if the following are true:~    * Received primary radiotherapy~   * No concurrent corticosteroids or has been on a stable corticosteroid dose for at least 30 days~   * No concurrent enzyme-inducible anti-epileptic medications (i.e., carbamazepine or phenytoin)~ * Multiple myeloma~ * Non-Hodgkin's lymphoma~* No refractory or relapsed acute or chronic leukemia~* Measurable or evaluable disease~* No life-prolonging therapy available~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Male or female~Menopausal status~* Not specified~Performance status~* ECOG 0-1~Life expectancy~* At least 4 months~Hematopoietic~* WBC at least 4,000/mm\^3~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10 g/dL~Hepatic~* Bilirubin no greater than upper limit of normal (ULN)~* AST and/or ALT no greater than 2.5 times ULN if alkaline phosphatase less than ULN OR~* Alkaline phosphatase no greater than 4 times ULN if AST/ALT less than ULN~Renal~* Creatinine no greater than 1.5 mg/dL OR~* Creatinine clearance at least 60 mL/min~Cardiovascular~* No New York Heart Association class III or IV heart disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 2 effective methods of contraception 4 weeks before, during, and 4 weeks after study~* Willing and able to comply with FDA-mandated STEPS program~* No peripheral neuropathy grade 2 or greater~* No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered~* No more than 2 prior courses of mitomycin~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* At least 4 weeks since prior large-field radiotherapy and recovered~Surgery~* Not specified~Other~* At least 3 weeks since other prior anticancer therapy and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).